SCHEMBL20005635

SCHEMBL20005635

c1cnc2c3ccc(o3)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
NPC1 O15118 4/20 0.46
HSP90AA1 P07900 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
NCOA1 Q15788 1/20 0.46
KDM4E B2RXH2 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
ALDH1A1 P00352 4/20 0.44
MAPT P10636 7/20 0.43
LIMK1 P53667 1/20 0.43
LMNA P02545 5/20 0.42
HTT P42858 3/20 0.42
USP2 O75604 2/20 0.42
RAB9A P51151 2/20 0.42
TP53 P04637 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
APAF1 O14727 1/20 0.41
TDP2 O95551 1/20 0.41
CASP3 P42574 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27174137 0.93 KMT2A (0.58) KMT2AMEN1NPC1HSP90AA1L3MBTL1
SCHEMBL29625837 0.93 KMT2A (0.58) KMT2AMEN1NPC1HSP90AA1L3MBTL1
SCHEMBL148991 0.93 KMT2A (0.58) KMT2AMEN1NPC1HSP90AA1L3MBTL1
Triphenylene SCHEMBL29177920 0.91 KMT2A (0.56) KMT2AMEN1NPC1HSP90AA1L3MBTL1
Acetic Acid SCHEMBL7978947 0.87 KMT2A (0.45) KMT2AMEN1NPC1HSP90AA1L3MBTL1
Pyridine SCHEMBL15673026 0.85 KMT2A (0.50) KMT2AMEN1NPC1HSP90AA1L3MBTL1
Dibenzothiophene SCHEMBL28528093 0.82 KMT2A (0.47) KMT2AMEN1NPC1HSP90AA1L3MBTL1
SCHEMBL16482063 0.81 NPC1 (0.44) KMT2AMEN1NPC1HSP90AA1L3MBTL1
SCHEMBL15835964 0.81 NPC1 (0.44) KMT2AMEN1NPC1HSP90AA1L3MBTL1
SCHEMBL15835963 0.81 NPC1 (0.44) KMT2AMEN1NPC1HSP90AA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220218676-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2022-07-14 US disclosed
US-20210015800-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. 2021-01-21 US disclosed
US-10806724-B2 Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use MERCK SHARP & DOHME CORP. (US) 2020-10-20 US disclosed
US-20190247374-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2019-08-15 US disclosed
US-10335399-B2 Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use MERCK SHARP & DOHME CORP. 2019-07-02 US disclosed
US-20180085358-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210015800-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE GRM2, GRIN2A, GRIA2 KMT2A 329/4885MEN1 3344/4885NPC1 409/4885
US-20220218676-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE GRM2, GRIN2A, GRIA2 KMT2A 353/4885MEN1 3984/4885NPC1 374/4885
US-10335399-B2 Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use GRM2, GRIN2A, GRIA2 KMT2A 344/4885MEN1 3719/4885NPC1 400/4885
US-20190247374-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE GRM2, GRIN2A, GRIA2 KMT2A 353/4885MEN1 3984/4885NPC1 374/4885
US-10806724-B2 Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use GRM2, GRIN2A, GRIA2 KMT2A 351/4885MEN1 3762/4885NPC1 397/4885
US-20180085358-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE GRM2, GRIN2A, GRIA2 KMT2A 351/4885MEN1 3762/4885NPC1 397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.